Research programme: asthma therapy - GlaxoSmithKline/Ventaira
Alternative Names: Asthma therapy research programme - GlaxoSmithKline/VentairaLatest Information Update: 15 Jan 2008
At a glance
- Originator GlaxoSmithKline; Ventaira Pharmaceuticals
- Developer Battelle; GlaxoSmithKline
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 29 Oct 2007 Ventaira Pharmaceuticals has been acquired and merged into Battelle
- 08 Jan 2004 BattellePharma is now called Ventaira Pharmaceuticals
- 29 Oct 2002 Preclinical trials in Asthma in USA (Inhalation)